C12N 2795/10134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/10134 (Use of virus or viral component as vaccine) appears on 7 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 8
- Assignees
- 5
- Inventors
- 8
- Latest grant
- 16 Jul 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 2 | 2 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 2 | 1 |
By publication year.
Recent patents
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells16 Jul 2024US 12,037,597 B2The Catholic University of America
- Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof9 Apr 2024US 11,952,594 B2Eligo Bioscience
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis11 Jan 2022US 11,219,686 B2The Catholic University of America
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells26 Oct 2021US 11,155,835 B2The Catholic University of America
- Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof21 Sep 2021US 11,124,776 B2Eligo Bioscience
- Bacterial delivery vehicle, process of production and uses thereof27 Jun 2024US 2024/0209326 A1
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells13 Jan 2022US 2022/0010335 A1The Catholic University of America
- Bacterial delivery vehicle, process of production and uses thereof9 Dec 2021US 2021/0380953 A1Eligo Bioscience
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells25 Feb 2021US 2021/0054410 A1The Catholic University of America
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis14 May 2020US 2020/0147207 A1The Catholic University of America
Most cited
By later US patents
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells2US 11,155,835 B2The Catholic University of America · 2021
- Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof1US 11,124,776 B2Eligo Bioscience · 2021
- Immunogenic compositions comprising silicified virus and methods of use1US 9,993,543 B2Portland State University · 2018